VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 9, 2015) - bioMmune Technologies Inc. ("bioMmune" or the "Company") (TSX VENTURE:IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, is pleased to announce that Patrick W. Gray, PhD and Reinhard Gabathuler, PhD have been elected as directors of the Company at its Annual and Special Meeting held on December 8, 2015 in Vancouver, B.C.

Dr. Gray has spent 35 years in the biotechnology industry, focusing on drug discovery for critical diseases. He has a passion for working in small companies with aggressive timelines -- Genentech, ICOS, Macrogenics, Nura and Accelerator were all less than 60 employees when he joined. Dr. Gray's career accomplishments include the first cloning and characterization of Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), Macrophage Derived Chemokine, and PI3K p110-delta. These discoveries led to numerous clinical trials, several approved human pharmaceuticals, and characterization of targets for therapeutic monoclonal antibodies and small molecules. In addition to his scientific accomplishments, Dr. Gray previously held senior scientific management positions, including Vice President, Chief Scientific Officer, and CEO. Dr. Gray received his PhD. in chemistry from the University of Colorado and his BS in biology from the University of Oregon. He is currently an affiliate professor at the University of Washington. Dr. Gray is also Chief Scientific Officer of the Company.

Dr. Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982, and completed postdoctoral studies at the University of Washington, Seattle. Over the years, he has held various research positions at the Swiss Institute for Experimental Cancer Research, Lausanne; the Ludwig Institute for Cancer Research at the Karolinska Institutet, Stockholm, Sweden; and the Biotechnology Laboratory of the University of British Columbia, Vancouver, Canada. His research on new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he became the Vice President of Research. The company was later acquired by BioMarin Pharmaceutical Inc., where Dr. Gabathuler assumed the position of Vice President of Brain Research. Dr. Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company's product ANG1005 to IND application and into the clinic. He is now involved as Chief Scientist at biOasis Technologies Inc. in the development of new peptide vector, Transcend for delivery of molecular cargo through the blood brain barrier. Dr. Gabathuler is also President and CEO of bioMmune.


The Company is also pleased to announce that Karoly Nikolich, PhD has been appointed as Chairman of the Board of Directors.

Dr. Nikolich is a renowned biotechnology expert with an extensive track record within this industry. Highlights include: former head of the Neuroscience Program at Genentech Inc.; Adjunct Professor, Neuroscience, USC, Los Angeles, CA; Vice President, Research, Lynx Therapeutics, Inc. Hayward, CA and Director (Supervisory Board) BASF-LYNX Bioscience AG, Heidelberg; former CEO, Amnestix, Inc., and Neurofluidics, Inc., Burlingame, CA; Executive Director, Neuroscience Institute at Stanford (NIS), Stanford University Medical School; Founder, Chief Executive Officer, and Director (Board member) AGY Therapeutics, Inc., South San Francisco, CA; and currently Dr. Nikolich is Founder and President of Circuit Therapeutics, Inc., and a consulting Professor at Stanford University Medical School. Along with an extensive professional history, Dr. Nikolich has been an author on over 120 scientific and review publications.

The Company also would like to announce that Robin Hutchison and J. Michael Hutchison have stepped down as directors of the Company. The Board of Directors would like to thank them for their contributions and wish them well in their future endeavors.

Following the Annual and Special Meeting held on December 8, 2015, members of the Board of Directors are:

Dr. Reinhard Gabathuler, President and CEO
Dr. Patrick Gray, Chief Scientific Officer
Dr. Karoly Nikolich, Chairman of the Board
Dr. Terry Pearson
Jens Biertumpel


bioMmune Technologies Inc. is a biopharmaceutical company that is advancing technologies focused on cancer, infectious and autoimmune diseases. Three significant technologies are:

  1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.
  2. Exploiting the regulation of calcium channel activity which is very important for controlling cells involved in the immune system. By regulating these calcium channels, immune activity can be controlled in ways to improve their ability to combat cancers, infections and autoimmune diseases.
  3. Modulating CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Dr. Reinhard Gabathuler, President

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

bioMmune Technologies Inc.
Dr. Reinhard Gabathuler